



Suspect systemic allergic reaction?  
Measure tryptase levels twice.



## Why tryptase?

**Tryptase** is a useful biomarker that can aid in systemic allergic reaction investigations<sup>1,2</sup> as it has been shown to be **released into the circulatory system during anaphylaxis**.<sup>2,3</sup> Paired acute and baseline tryptase levels aid in differential diagnosis (including mastocytosis or other mast cell disorders), patient management and follow up care.

Whenever you suspect systemic allergic reaction  
**measure tryptase levels twice**



\*serum Acute Tryptase \*\*serum Baseline Tryptase

If the change ( $\Delta$ ) in tryptase levels (sAT - sBT) is  $\geq 20\%$  of the individual's sBT + 2 µg/l then mast cell activation is indicated.<sup>1,4,6-8</sup>

Note: seemingly normal serum tryptase levels do not preclude that an anaphylactic reaction has occurred.<sup>1-3,7-9</sup> Performing the calculation can help identify possible mast cell activation that might otherwise be missed.<sup>4,9</sup>



When systemic allergic reaction is suspected, tryptase testing is recommended by global allergy organizations, including WAO, AAAAI/ACAAI, and EAACI<sup>1-4,6,8,10</sup>

## Systemic allergic reaction & COVID-19 vaccines

Although still rare, to date, the incidence rate of anaphylaxis associated with first doses of three major COVID-19 vaccines exceeds the estimated incidence rate of anaphylaxis associated with other types of vaccines (2 to 11.1 per million vs approximately 1 per million).<sup>5,11-14,16,17</sup>

## Guidelines for tryptase testing in suspected COVID-19 vaccine-associated anaphylaxis

Global allergy organizations recommend tryptase testing as **critically important** for accurate diagnosis of COVID-19 vaccine-associated anaphylaxis. Affected patients should be advised to follow-up with a specialist (e.g., allergist, immunologist) to determine if a second dose of COVID-19 vaccine should be given.<sup>11,12,16-18</sup>

## Whenever you suspect systemic allergic reaction measure tryptase levels twice

### References

1. Valent *et al.* Definitions, criteria, and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. *Int Arch Allergy Immunol.* 2012;157(3):215-25.
2. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. *Immunol Allergy Clin North Am.* 2006 Aug;26(3):451-63.
3. Lieberman *et al.* The diagnosis and management of anaphylaxis practice parameter: 2010 update. *J Allergy Clin Immunol.* 2010 Sep;126(3):477-80.
4. Vitte *et al.* Use and Interpretation of Acute and Baseline Tryptase in Perioperative Hypersensitivity and Anaphylaxis. *J Allergy Clin Immunol.* 2021 Mar 18;S2213-2198(21)00315-9. DOI: 10.1016/j.jaip.2021.03.011.
5. Schwartz LB, Yunginger JW, Miller JS *et al.* The time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. *J Clin Invest.* 1989 May;83(5):1551-5.
6. Cardona *et al.* World allergy organization anaphylaxis guidance 2020. *World Allergy Organ J.* 2020 Oct 30;13.
7. Simons FE *et al.* International consensus on (ICON) anaphylaxis. *World Allergy Organ J.* 2014 May;30(7):9
8. Simons FE *et al.* World Allergy Organization anaphylaxis guidelines: Summary. *J Allergy Clin Immunol.* 2011 Mar;127(3):587-93.
9. Simons FE *et al.* 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. *World Allergy Organ J.* 2015 Oct 28;8(1):32.
10. Muraro *et al.* Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. *Allergy.* 2014 Aug;69(8):1026-45.
11. Sokolowska *et al.* EAACI statement on the diagnosis, management, and prevention of severe allergic reactions to COVID-19 vaccines. *Allergy.* 2021 Jan 16.
12. Klimek *et al.* ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines—an EAACI-ARIA Position Paper. *Allergy.* 2020 Dec 30.
13. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. *MMWR Morb Mortal Wkly Rep* 2021; 70:46–51. DOI: <http://dx.doi.org/10.15585/mmwr.mm7002e1>
14. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020–January 10, 2021. *MMWR Morb Mortal Wkly Rep* 2021; 70:125–129. DOI: <http://dx.doi.org/10.15585/mmwr.mm7004e1>
15. COVID-19 vaccine safety update for Vaxzevria, AstraZeneca AB. (2021, March 29). European Medicines Agency. [https://www.ema.europa.eu/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021\\_en.pdf](https://www.ema.europa.eu/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf)
16. Turner *et al.* COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. *World Allergy Organ J.* 2021 Feb;14(2):100517.
17. American College of Allergy, Asthma, and Immunology (ACAAI). (2021, March 11). ACAAI Updates to Guidance on Risk of Allergic Reactions to COVID-19 Vaccines. [Press Release]. <https://acaai.org/news/acaai-updates-guidance-risk-allergic-reactions-covid-19-vaccines>
18. US Centers for Disease Control and Prevention (CDC), referred to by AAAAI. (2021, April 8). Lab Tests to Collect Shortly After Severe Allergic Reaction/Anaphylaxis Following COVID-19 Vaccination [https://www.cdc.gov/vaccines/covid-19/clinical-considerations/testing-after-allergic-reaction.html?CDC\\_AA\\_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F%2Fclinical-considerations%2F%2Fanaphylaxis-management.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/testing-after-allergic-reaction.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2F%2Fclinical-considerations%2F%2Fanaphylaxis-management.html)

Find more resources at [thermofisher.com/measuretryptasetwice](https://thermofisher.com/measuretryptasetwice)

The cleared intended use of ImmunoCAP Tryptase differs in the United States.

© 2021 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. **152870.AL.EU, INT1.EN.v8.21**

**ThermoFisher**  
SCIENTIFIC